Summary
This is an early-stage study to test the safety and immune response of a new mRNA vaccine, mRNA-1189, designed to prevent Epstein-Barr virus (EBV) infection. It will enroll 120 healthy adults aged 18-30 to receive the vaccine either as a shot in the skin or muscle. The main goals are to see how safe the vaccine is and whether it triggers a protective immune response against the virus.
Follow this study
Save this study to your dashboard
Sign up to follow this study so you can find it again quickly and keep track of it from your dashboard.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Doherty Clinical Trials
Melbourne, Victoria, VIC 3149, Australia
-
Nucleus Network
Melbourne, Victoria, VIC 3004, Australia
Conditions
Explore the condition pages connected to this study.